Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLoans and Notes ReceivablesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Accumulated Depreciation & Amortization (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Accumulated Depreciation & Amortization over the past 15 years, most recently at $8.0 million for Q2 2025.

  • For Q2 2025, Accumulated Depreciation & Amortization rose 0.92% year-over-year to $8.0 million; the TTM value through May 2025 reached $8.0 million, up 0.92%, while the annual FY2025 figure was $8.0 million, 0.92% up from the prior year.
  • Accumulated Depreciation & Amortization for Q2 2025 was $8.0 million at Lifecore Biomedical, Inc. \De\, up from $2.1 million in the prior quarter.
  • Over five years, Accumulated Depreciation & Amortization peaked at $19.9 million in Q2 2021 and troughed at $2.0 million in Q4 2023.
  • A 5-year average of $8.4 million and a median of $7.6 million in 2022 define the central range for Accumulated Depreciation & Amortization.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: rose 11.89% in 2021 and later plummeted 72.76% in 2023.
  • Year by year, Accumulated Depreciation & Amortization stood at $11.0 million in 2021, then tumbled by 33.65% to $7.3 million in 2022, then plummeted by 72.76% to $2.0 million in 2023, then increased by 2.87% to $2.0 million in 2024, then skyrocketed by 292.71% to $8.0 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for LFCR at $8.0 million in Q2 2025, $2.1 million in Q1 2025, and $2.0 million in Q4 2024.